Senior Life Science

Consulting and

Advisory for

Lean Biotech




The expertise you need - when it matters most

StamKire supports emerging pharma and biotech companies make better development decisions and deliver on them.



We combine strategic advisory with
hands-on consulting: helping you define
the right path, then supporting the work
needed to move forward.

From scientific opportunity and
preclinical development to
clinical strategy, technical
assessment and company
growth, we bring senior expertise
without the cost or complexity
of a large consultancy.




Two independent  Swedish consultants. One integrated team.
No junior handovers, no unnecessary layers and no advice that disappears into a slide deck.

Small enough to be agile. Senior enough to make a difference.


Complementary strength - one integrated team


StamKire combines experience across preclinical and clinical development, biotechnology, chemistry, R&D operations and strategic execution. Together, we bring scientific depth, practical industry experience and a collaborative, hands-on approach to the decisions that shape a programme’s next stage.

Mats Holmquist, PhD, Assoc Prof

CEO, Co-founder : Strategic R&D leadership for the next stage of growth

Mats brings more than 30 years of experience in research and development leadership, including 18 years at BioArctic AB. During that time, he served on the management team and scientific board, contributing to the company’s development from an agile start-up into a profitable Nasdaq Stockholm-listed organisation with approximately 200 employees. His experience includes the development journey of Leqembi® (lecanemab), from early discovery through clinical development to patients worldwide. This gives Mats a rare perspective on the scientific, technical, regulatory and organisational work required to build a programme and a company over the long term.

Mats understanding of the startup journey is rooted in hands-on experience. Early in his career, he was part of the rapid growth of Gyros Protein Technologies AB—a spin-off from Amersham Pharmacia Biotech—as it scaled from 30 to over 100 employees.  Working as a Project Manager and Senior Scientist, he  worked closely across teams integrating the development of hardware, software, CD consumables, and applications, while actively supporting the product launches of the  developed Gyrolab® technology  and   Gyrolab® discs, by presentations to Big Pharma at international conferences. Being part of that journey taught him what it takes to bring novel  innovative technologies and products  to market.  

Alongside his extensive industry experience, Mats also bring a solid understanding of the academic research landscapes and conditions, as an Affiliated  Associate Professor in Biochemistry (Docent)  at the Royal Intitute of Technology in Stockholm for more than 25 years.

Today, he advises start-up, early-stage and growing life-science companies as they prepare for critical development milestones, technical scale-up and organizational growth. He helps leadership teams make robust decisions in areas where scientific opportunity, operational capability and business value need to align. The aim is not simply to add processes, meetings or impressive-looking arrows to a slide; it is to create the right level of structure for progress.

Mats is known for combining scientific depth with clear strategic thinking and a pragmatic leadership style. He supports teams in addressing both the immediate decision in front of them and the capabilities they will need for the next stage of growth.

Areas of support

  • Strategic R&D leadership and scale-up of teams and organisations

  • Preclinical and clinical development strategy

  • Biotechnology, CMC and technical development assessment

  • CMC strategy, GMP readiness and external manufacturing partnerships

  • Scientific, regulatory and technical due diligence

  • Non-dilutive funding, grant strategy and application review

  • Board, investor and partner communication

  • Building practical decision-making structures for growing R&D organisations

#BiotechStartup #PharmaConsulting #DrugDevelopment
#BiotechFounder #BioArctic #CMC #LifeSciences

Erik Rollman Waara, PhD

Co-founder: Turns scientific opportunities to development strategies

Erik has more than 25 years of experience in life-science  and development, spanning early research, preclinical development and clinical-stage biotech. He has worked in both entrepreneurial and established settings, giving him a practical understanding of the trade-offs teams face when ambition, timelines and budgets all compete for attention.

During his time at BioArctic AB, Erik contributed hands-on to the preclinical research programme, establishing assays, conducting in vivo studies and helping build a fully equipped laboratory. The lead candidate, mAb158, was developed into BAN2401 and ultimately became Leqembi® (lecanemab), which is approved for the treatment of Alzheimer’s disease.

At Sigrid Therapeutics AB, Erik led preclinical development and helped establish the capabilities needed to advance the programme. At Atrogi AB, he has taken the next step—driving preclinical toxicology, CMC and the processes supporting the first-in-human (FIH) trial. The breadth of this development journey, from basic science to clinical translation, was recently described in the journal Cell.

Erik’s strength is connecting science with the development path: identifying the evidence needed, pinpointing key risks and shaping a focused, value-creating way forward. He works closely with founders, management teams and scientific leaders to turn complex opportunities into clear strategies, credible plans and practical next steps. He brings an analytical, collaborative and hands-on approach. Equally comfortable discussing programme details, constructively challenging assumptions and coordinating the work required to keep development moving,

Areas of support

  • R&D strategy, asset positioning and development planning

  • Preclinical development, study design and data interpretation

  • Translational strategy and transition to first-in-human studies

  • Early clinical strategy, programme coordination and execution

  • Outsourcing strategy, CRO selection and partner management

  • Pharma collaborations, scientific partnerships and due diligence

  • R&D organisation, capability building and digital ways of working

  • Scientific communication for boards, investors and external stakeholders

#BiotechConsulting #DrugDevelopment #R&D #PreclinicalDevelopment #ClinicalDevelopment #LifeSciences #Pharma #ClinicalTrials

Where we contribute

Discover the unique advisory services we offer to help your business thrive.

Development strategy and programme execution

We help turn scientific opportunities into focused development plans—from early strategy through clinical planning and critical milestones.

  • Development strategy an
     roadmap planning

  • Preclinical-to-clinical translation

  • Program prioritization and risk
     assessment

  • Clinical development strategy
     and evidence generation

  • Interim leadership and cross-functional program support

Drug Discovery & Development

We support programmes from discovery through preclinical and early clinical development, helping teams design the right studies, interpret data and evidence and make clear next-step decisions. Our experience includes:

  • Small molecules

  • Biopharmaceuticals and monoclonal antibodies

  • Enzymes and biomarkers

  • Biodegradable drug-delivery materials

  • Biotechnology, chemistry and technical development

Regulatory  & intellectual property strategy

Good regulatory and IP planning should support asset value—not arrive as a last-minute fire drill. We provide support with:

  • Regulatory development strategy

  • Scientific interactions with regulatory authorities

  • Patent strategy and asset-value assessment

  • Innovation and patent-claim authorship

  • Regulatory and scientific due diligence

R&D operations, data and digital tools

As programmes grow and move through research and development phases, the ways of working need to be stream-lined, adapted and  fit for the purpose, along the line. We help build lean and practical R&D capability without adding unnecessary processes, and can support with:

  • R&D organisation and capability design

  • Outsourcing strategy design, CRO
    selection and management

  • External partner management

  • Design and implementation of IT-enabled working practices and digital tools for efficient R&D data storage, management and protection

Funding, communication and partnering

We translate complex science and development plans into materials for fund raising,  efficient  decision making, and productive communication between scientists, investors, boards and business partners.

  • Grant applications and review

  • European Commission and EIC advisory support

  • Business-development and outreach planning

  • Investor, partner and board communication

  • Scientific and strategic presentations


How we work

StamKire is a close partnership between two Swedish consultants. We tailor each engagement to your development stage, priorities and budget and to the level of support you actually need.

Some assignments are primarily advisory: an independent assessment, a development strategy, a due-diligence review or help making a critical decision.

Many are operational consulting assignments. In these, we become part of the working team and help deliver the programme: leading workstreams, coordinating internal and external stakeholders, managing CROs and partners, developing plans and materials, resolving issues and maintaining momentum.

You receive:

  • Direct access to senior specialists who do the work themselves

  • Strategic advice grounded in first-hand development experience

  • Operational capacity where your team needs it most

  • A clear, proportionate scope and pragmatic way of working

  • Support from a focused assignment to interim leadership or long-term program delivery

Whether you need expert judgement, hands-on delivery or both, we adapt to your programme, not the other way around.

Big milestones. Lean teams.
Little room for guesswork.

Early stage and growing life-science companies make important decisions with limited time, resources and internal bandwidth. The challenge is rarely a lack of ambition or good science. It is having the right experience available at the moment a programme needs to move.

StamKire connects scientific understanding, development strategy, technical depth and operational reality.

We help teams:

  • Make confident development decisions

  • Build credible, executable plans

  • Focus resources on what matters most

  • Manage risks before they become
    expensive surprises

  • Communicate complex programmes
    clearly to investors, boards, partners and regulators

Why StamKire?

Advisors that can also do the work!

Advisory is an important part of what we do: helping you assess options, set direction and make sound decisions.  But it is only part of the job. More importantly, we work alongside your team to deliver. We can take operational responsibility, drive workstreams, manage external partners, prepare critical materials and keep programs moving through the everyday complexity of drug development.

We bring the strategic perspective to choose the right path and the hands-on capacity to move down it. Fewer recommendations left in a presentation and more meaningful progress in the program.

This is how we have worked throughout our careers, not just advising from the sidelines, but getting the job done.

Like Hand A line styled icon from Orion Icon Library.

Integrated,
not fragmented

We work as one team across scientific, technical, strategic and operational questions. That means fewer handovers, fewer gaps and more connected decisions.

Call Contact A line styled icon from Orion Icon Library.

Senior expertise only

The people you meet do the work. You receive direct access to experienced advisors and consultants, not a pyramid of junior staff.

Agenda A line styled icon from Orion Icon Library.

Agile and Scalable 

 Engage us for a focused assessment, interim leadership or longer term support as your program and organisation develop.

Bank Cards A line styled icon from Orion Icon Library.

Cost effective

Access complementary senior expertise without the permanent cost of multiple full time functions or the overhead of a large consultancy.

Frequently Asked Questions

Get clarity on our services and how we can help you.

What do you do?

We provide consulting and advisory support across discovery, preclinical and clinical development, biotechnology, chemistry, regulatory strategy, intellectual property, R&D operations and strategic communication.

How do you tailor your services?

We match the scope to your stage, budget and priorities. This can range from a targeted expert assignment to interim capacity or ongoing strategic and operational support.

Where are you located?

We are based in Sweden and work closely with clients in Uppsala and Stockholm, as well as across Scandinavia and Europe.

What makes you different from a large consultancy?

You work directly with two senior specialists who combine strategic perspective with practical delivery. We offer broad capability, quick decisions and less overhead, without making a small project feel like a major procurement exercise.